Abstract
e16539Background: Abiraterone (A) and enzalutamide (E) are life-prolonging treatments for metastatic CRPC, yet their potent activity against the androgen receptor (AR) axis often yields tumors that...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
